JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Part of paid clinical trials in Denver, Colorado.

Sponsor
Jacobio Pharmaceuticals Co., Ltd.
Study ID
NCT06386146
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JAB-30355 — DRUG
    Oral administration
  • JAB-30355 — DRUG
    Oral administration

Study Details

This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.

Key Dates

Start date
Jul 24, 2024
Status verified
May 2026
Primary completion
Jan 31, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
144 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose escalation phase
    Multiple dose levels of JAB-30355 will be explored to determine the maximum tolerated dose (MTD)
  • Experimental: Dose expansion phase
    Dose Expansion Phase will explore JAB-30355's clinical benefit and optimal tolerability in selected dose level.

Primary Outcome Measure

Dose limiting toxicity (DLT) [ Time Frame: Approximately one year ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Research SiteDenverColorado80218-
Research siteLake MaryFlorida32771-
Research siteSt LouisMissouri63110-
Research siteCantonOhio44718-
Research siteClevelandOhio44195-
Research SiteNashvilleTennessee37203-
Research siteHoustonTexas77030-

Find similar trials in Denver, CO

By research site
Research Site· Denver, COResearch site· Lake Mary, FLResearch site· St Louis, MOResearch site· Canton, OHResearch site· Cleveland, OHResearch Site· Nashville, TN

Related Studies